Recent Advances in Zika Virus Vaccines
AbstractThe recent outbreaks of Zika virus (ZIKV) infections and associated microcephaly in newborns has resulted in an unprecedented effort by researchers to target this virus. Significant advances have been made in developing vaccine candidates, treatment strategies and diagnostic assays in a relatively short period of time. Being a preventable disease, the first line of defense against ZIKV would be to vaccinate the highly susceptible target population, especially pregnant women. Along those lines, several vaccine candidates including purified inactivated virus (PIV), live attenuated virus (LAV), virus like particles (VLP), DNA, modified RNA, viral vectors and subunit vaccines have been in the pipeline with several advancing to clinical trials. As the primary objective of Zika vaccination is the prevention of vertical transmission of the virus to the unborn fetus, the safety and efficacy requirements for this vaccine remain unique when compared to other diseases. This review will discuss these recent advances in the field of Zika vaccine development. View Full-Text
Share & Cite This Article
Garg, H.; Mehmetoglu-Gurbuz, T.; Joshi, A. Recent Advances in Zika Virus Vaccines. Viruses 2018, 10, 631.
Garg H, Mehmetoglu-Gurbuz T, Joshi A. Recent Advances in Zika Virus Vaccines. Viruses. 2018; 10(11):631.Chicago/Turabian Style
Garg, Himanshu; Mehmetoglu-Gurbuz, Tugba; Joshi, Anjali. 2018. "Recent Advances in Zika Virus Vaccines." Viruses 10, no. 11: 631.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.